Who we are

About Tikun Europe

Tikun Europe is a company that cultivates, processes and merchandises industrial and pharmaceutical cannabis on a 56.000 square meters site, 80km west of Athens, at Corinth. It produces cannabis medicinal products, in accordance to Good Manufacturing Practices and FDA Standards. The facility unit deals with the greenhouse cultivation and industrial processing of cannabis flowers for the production of medicinal products. Tikun Olam provides Tikun Europe with the very competitive advantage of one of the most reputable name in the global medical cannabis industry in combination with a specialized know-how and an extensive clinical research. The company is dedicated to improve patients' treatments, wellness and overall quality of life. Furthermore, Tikun Europe exploits an extensive patient treatment database of over 30.000 patients in order to provide and develop the most resulting medical cannabis products.

Mission

Our mission is to bring cure and alleviation providing evidence based medical cannabis treatment worldwide.

Grow

Medical cannabis cultivated in state-of-the-art standards, with award-winning proprietary strains that have been genetically optimized to maximize symptomatic relief.

Research

With more than 10 years of clinical trials and
laboratory studies, Tikun has a successful record of treating ailments like cancer pain, Crohn’s, Parkinson’s, autism, & epilepsy and holds unprecedented patient clinical data collection, with over 30.000 patient records. This extensive research and database provides Tikun Europe the great advantage of access to knowledge and insights that no other competitor has in the medical cannabis industry.

Manufacture

The production is carried out in accordance with the EU GMP standards, with proprietary formulation and extraction techniques, ensuring consistent products that deliver consistent results.

Supply

A discrete and safe distribution system in accordance with EU Good Distribution Practices.

Roadmap

2005 Establishment of Tikun Olam Israel

2014 Co-founder Medreleaf pioneers in the Canadian medical cannabis industry

2016Established Tikun Olam USA operating in Nevada, Washington, Rhode Island, Maryland, Massachusetts, Illinois and California

2017Co-founder Medifarm Australia: Queensland's first licensed medicinal cannabis developer

2021Establishment of Tikun Europe Rep. Offices

2018

Establishment of Tikun Europe

2020Production Facility Tikun Europe

2005

Establishment of Tikun Olam Israel

2014

Co-founder Medreleaf pioneers in the Canadian medical cannabis industry

2016

Established Tikun Olam USA operating in Nevada, Washington, Rhode Island, Maryland, Massachusetts, Illinois and California

2017

Co-founder Medifarm Australia: Queensland's first licensed medicinal cannabis developer

2018

Establishment of Tikun Europe

2020

Production Facility Tikun Europe

2021

Establishment of Tikun Europe Rep. Offices

Company overview

A 21,000m2 greenhouse cultivation area has been designed to provide efficient conditions for medical cannabis plants growing using state of the art systems and automations.
The greenhouses will be fully compliant to EU GACP standards, assuring the highest quality of the cultivated plants.

Why Tikun?

Tikun is one of the most reputable and trusted brands among the medical cannabis industry. It holds a great track-record of clinical research, know-how and awards for its special production of strains.
The brand Tikun was introduced in the market in 2005 with the establishment of Tikun Israel. Since then, the brand has further been developed with the establishment of MedReleaf in Canada in 2014 which was acquired by Aurora in 2018. Afterwards the establishment of Tikun USA took place in 2016, then Medifarm-Tikun Oceania in 2017, and finally Tikun Europe in 2018, with state-of-the art facilities.

At the forefront of cannabis treatment research in Israel
More than ten years of clinical trials and laboratory studies successfully treating ailments like cancer pain,
Crohn’s, Parkinson’s, autism, & epilepsy
One of the world’s largest treatment databases, with over 30,000 patient records — and growing daily
Award-winning proprietary Israeli strains that have been genetically optimized to maximize symptomatic relief
Proprietary formulation and extraction techniques, ensuring consistent products that deliver consistent results
Global footprint with tens of thousands of patients , including best-selling strains worldwide

Why Greece?

Since the legalization of medical cannabis production and export in Greece, in March 2018, there are several companies willing to take advantage of the market. Medical cannabis use was legalized in Greece in June 2017. Shortly, in March 2018, Greece introduced law 4523/2018 allowing the farming processing of medical cannabis.

If Greece were to benefit from medical cannabis to the same extent as other countries that have introduced medical cannabis, it could inject up to EUR 2 Billion into the economy. Greece has great potential for developing a strong cannabis industry both for medical and industrial applications due to its geomorphology and climate conditions.

Ideal location of the facility since it constitutes the tipping point of connection among West Europe, Greece and Middle East.

Climate conditions are suitable for lower set up and manufacturing costs.

Low labour cost in comparison to the other European countries.

Financial growth and political stability.

Scroll Up